Retractable Technologies, Inc. (NYSE:RVP) CEO Acquires $58,566.04 in Stock

Retractable Technologies, Inc. (NYSE:RVP) CEO Thomas J. Shaw bought 71,422 shares of the company’s stock in a transaction on Friday, September 20th. The stock was bought at an average cost of $0.82 per share, with a total value of $58,566.04. Following the completion of the purchase, the chief executive officer now owns 14,743,907 shares of the company’s stock, valued at approximately $12,090,003.74. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Retractable Technologies Stock Down 3.3 %

NYSE RVP opened at $0.73 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.54 and a current ratio of 9.51. Retractable Technologies, Inc. has a 52 week low of $0.71 and a 52 week high of $1.34. The stock has a market capitalization of $21.71 million, a P/E ratio of -2.79 and a beta of 2.08. The stock has a fifty day moving average of $0.98 and a 200-day moving average of $1.06.

Retractable Technologies (NYSE:RVP) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.48) EPS for the quarter. Retractable Technologies had a negative return on equity of 18.67% and a negative net margin of 46.72%. The firm had revenue of $6.03 million during the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Retractable Technologies in a research report on Tuesday. They issued a “hold” rating for the company.

About Retractable Technologies

Retractable Technologies, Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes.